Indian Pharmacopoeia Commission Signs MoUs with Bihar, Maharashtra and Mizoram State Pharmacy Councils to Strengthen Medicine Safety and Promote Rational Use of Medicines Nationwide

1. At a Glance

IPC (Ghaziabad), autonomous body under Ministry of Health & Family Welfare, signed three MoUs on 12 May 2026 with the Bihar, Maharashtra and Mizoram State Pharmacy Councils to deepen pharmacovigilance and rational drug use [S1].
UPSC relevance: ties together drug regulation architecture, PvPI (Pharmacovigilance Programme of India), cooperative federalism in health, and patient safety [S1][S2].

2. Why in the News

On 12 May 2026, IPC signed three MoUs at IPC, Ghaziabad to expand ADR (Adverse Drug Reaction) Monitoring Centres, strengthen PvPI, and promote rational use of medicines through state-level pharmacy councils [S1].
Part of IPC's wider 2025–26 push that included earlier MoUs with NIPER Hajipur and the Pharmaceuticals & Medical Devices Bureau of India (PMBI) [S3][S4].

3. Background & Evolution

IPC established 2009 (registered under Societies Registration Act, 1860) at Ghaziabad, UP, as autonomous body under MoHFW; publishes the Indian Pharmacopoeia (IP) to fulfil obligations under the Drugs & Cosmetics Act, 1940 [S5][S2].
PvPI launched 14 July 2010; NCC-PvPI (National Coordination Centre) shifted to IPC, Ghaziabad in April 2011 [S2].
9th edition of IP released 2022 (Mandaviya); 10th edition of IP released by Union Health Minister J.P. Nadda in 2025 [S6][S7].
India's rank in WHO global VigiBase ADR contributions rose from 123rd (2009–14) to 8th (2025) [S2].

4. Core Static Facts

Parent ministry: Ministry of Health & Family Welfare (NOT Dept. of Pharmaceuticals/Ministry of Chemicals & Fertilizers) [S1].
HQ: Ghaziabad, Uttar Pradesh [S1].
Enabling statute: Drugs and Cosmetics Act, 1940; state pharmacy councils are constituted under Pharmacy Act, 1948 [S5].
Signatories of 12 May 2026 MoUs:
Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC [S1].
Dr. Prakash Sinha, President, Bihar State Pharmacy Council [S1].
Mr. Atul Ahire, President, Maharashtra State Pharmacy Council [S1].
Dr. H. Lalhlenmawia, Vice-President, Mizoram State Pharmacy Council [S1].
PvPI helpline: 1800-180-3024; ADR PvPI 2.0 mobile app for ADR reporting [S2].
MoU deliverables: joint training, ADR monitoring centres in states, public awareness, technical support from IPC; state councils to coordinate with pharmacists, hospitals, healthcare institutions [S1].

5. Multi-Dimensional Analysis

Administrative / Federal: Operationalises cooperative federalism in drug safety — Union body (IPC) leveraging state statutory pharmacy councils (under Pharmacy Act, 1948) for last-mile ADR reporting [S1][S5].
Scientific / Technological: Promotes digital ADR reporting via PvPI 2.0 app, real-time data capture into VigiBase; strengthens India's contribution to WHO Programme for International Drug Monitoring (Uppsala Monitoring Centre) [S2].
Social / Public Health: Counters irrational drug use, antimicrobial resistance (AMR), self-medication; targets vulnerable populations through pharmacist-led awareness [S1][S2].
Economic: Reinforces credibility of Indian generics ("Pharmacy of the World"); IP standards underpin exports worth >US$25 bn p.a.; quality assurance reduces recalls [S6].
Governance / Ethical: Builds transparency in adverse-event reporting, patient-safety culture, and accountability of prescribers/pharmacists [S1].

6. Recent Developments (last 12–18 months)

12 May 2026 — IPC–Bihar/Maharashtra/Mizoram MoUs signed [S1].
2025 — 10th edition of Indian Pharmacopoeia released by Union Health Minister J.P. Nadda [S7].
17–23 Sept 2025 — National Pharmacovigilance Week themed "Your Safety, Just a Click Away: Report to PvPI"; launch of ADR PvPI 2.0 mobile app [S2].
IPC inducted into the Pharmacopoeial Discussion Group (PDG) alongside USP, EP, JP (a global harmonisation forum) [S8].
Earlier 2025–26 MoUs with NIPER Hajipur, PMBI, AMTZ, and Nagaland pharmacy/medical bodies [S3][S4][S9].

7. Prelims Hooks

IPC is headquartered at Ghaziabad, Uttar Pradesh [S1].
IPC is autonomous under Ministry of Health & Family Welfare (not Dept. of Pharmaceuticals) [S1].
Indian Pharmacopoeia is published to fulfil requirements of the Drugs & Cosmetics Act, 1940 [S5].
PvPI launched in 2010; NCC shifted to IPC in 2011 [S2].
India's global rank in WHO ADR database: 8th (2025), up from 123rd (2009–14) [S2].
10th edition of Indian Pharmacopoeia released in 2025 by J.P. Nadda [S7].
State Pharmacy Councils derive legal authority from the Pharmacy Act, 1948 [S5].
IPC is a member of the Pharmacopoeial Discussion Group (PDG) with USP, EP, JP [S8].
PvPI toll-free helpline: 1800-180-3024 [S2].
MoU signatory from IPC: Dr. V. Kalaiselvan, Secretary-cum-Scientific Director [S1].
IPC also runs Materiovigilance Programme of India (MvPI) for medical devices [S2].

8. Mains Relevance

GS-II: Government policies & interventions for sectors of health; issues relating to development and management of Social Sector/Services relating to Health.
GS-III: Science & Technology — indigenisation, IPR in pharma; Issues related to drug regulation.
Plausible stems: 1. "Discuss the institutional architecture for drug safety in India. How does IPC's collaboration with State Pharmacy Councils advance pharmacovigilance?" 2. "Rational use of medicines is critical to public health and AMR containment in India. Examine." 3. "Examine the role of the Indian Pharmacopoeia Commission in positioning India as the 'Pharmacy of the World'."

9. Related Topics to Study Next

Pharmacovigilance Programme of India (PvPI) — directly operationalised by the MoUs [S2].
Central Drugs Standard Control Organisation (CDSCO) & DCGI — apex drug regulator; complements IPC standards.
Pharmacy Act, 1948 & Drugs and Cosmetics Act, 1940 — statutory base [S5].
Antimicrobial Resistance (AMR) — National Action Plan — linked to rational drug use [S1].
Jan Aushadhi / PMBJP & PMBI — quality generics; IPC standards apply [S3].
NIPERs (National Institutes of Pharmaceutical Education & Research) — R&D partner [S3].
Materiovigilance Programme of India (MvPI) — medical-device safety analogue [S2].
WHO Uppsala Monitoring Centre / VigiBase — international ADR database [S2].

10. Common Errors / Trap Areas

IPC sits under MoHFW, not Dept. of Pharmaceuticals (which is under Ministry of Chemicals & Fertilizers).
IPC ≠ PCIM&H (Pharmacopoeia Commission for Indian Medicine & Homoeopathy) under Ministry of AYUSH [S10].
IPC publishes the Indian Pharmacopoeia; CDSCO/DCGI regulates approvals — distinct functions.
PvPI launched 2010, NCC moved to IPC in 2011 — years often confused.
State Pharmacy Councils derive power from Pharmacy Act, 1948, not the Drugs & Cosmetics Act.

11. Sources

[S1] IPC Signs MoUs with Bihar, Maharashtra and Mizoram State Pharmacy Councils — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2260365 — (tier: 1)
[S2] IPC inaugurates 5th National Pharmacovigilance Week — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2167578 — (tier: 1)
[S3] IPC Signs MoUs with PMBI and NIPER Hajipur — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2255190 — (tier: 1)
[S4] NIPER Hajipur Signs MoU with IPC — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2255260 — (tier: 1)
[S5] IPC Signs Three MoUs to Bolster Medicine Safety, Quality Standards — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2225435 — (tier: 1)
[S6] Mandaviya chairs IPC conference 2022; 9th edition of IP — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1838570 — (tier: 1)
[S7] Union Health Minister J.P. Nadda Releases 10th Edition of Indian Pharmacopoeia — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2210754 — (tier: 1)
[S8] Pharmacopoeial Discussion Group welcomes IPC as a member — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1966349 — (tier: 1)
[S9] IPC signs 3 MoUs with Nagaland Councils — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2195787 — (tier: 1)
[S10] Cabinet approves PCIM&H under AYUSH — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1629040 — (tier: 1)